SBIR/STTR Research Award

Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing

Award identifier 041fee0c319883ca44843ef5fcabcfaa9ce7da91ebafa3de0d092e15dfd3c152Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$984,242

Program and phase

SBIR · Phase II

Award year

2025

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
CELLCHORUS INC
Proposal award date
2025-05-01
Contract end date
2027-04-30
UEI
LUF6ANBGK7F4
Solicitation number
PA23-230
Topic code
100

Research abstract

ABSTRACT Cell and gene therapies have revolutionized treatment options for patients with pace of discovery and implementation accelerating. For example, clinical success of CAR-T cells for hematologic malignancies has led to use in expanded patient populations and trials targeting for other cancer types. While there are many cell therapies in preclinical development and clinical trials confidence in their successes is undermined by the inherent complexity of cells that remains difficult to decipher using existing tools. What is needed is an integrated analytical platform providing a matrix of readouts that reveal an in-depth real-time understanding of cell phenotype and metabolism. Such a platform will inform on the therapeutic potential before administration and by sampling patients will reveal aspects of cell behavior that correlate with efficacy. CellChorus is answering this need using our platform (“TIMING”) to undertake large scale single-cell analyses to track and characterize behavior of immune cells over time. TIMING uses sophisticated AI-based software, many years in development, to track and characterize behaviors of thousands of cells in parallel using time-lapse imaging. Multiple papers and repeat customers have helped validate our approach to commercialization. Based on users’ demand, we propose to advance TIMING by (i) developing and optimizing reagents and protocols to identify a suite of cell surface attributes, (ii) quantify proliferative capacity and (iii) determine metabolic activity before, during, and after cell-cell interactions. We will integrate these findings with our AI software to provide end users with a simple, unified assay system to run in their own laboratories on commercially available imaging instrumentation. The results of this project will be ready-to-use kits to reveal critical immune-biology of cells in critical and challenging environments. This is predicted to augment translational research and development leading to improvements in manufacturing and success in patients.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

8 SBIR/STTR records share this UEI (2023–2025). Reported award amounts total $5,813,959. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.